Growth hormone therapy and bone mineral density in Turner syndrome.
In a previous report, preliminary data showed a significant reduction in cortical bone mineral density (BMD) in women with Turner syndrome that had been treated with GH compared with women with Turner syndrome that had not been treated. To clarify this point, we have investigated the effects of GH treatment at multiple sites in this case-control, cross-sectional study. There were 23 women per group, who were similar in age, height, body mass index, estrogen use, and ethnic makeup. Median age (range) at start and duration of GH treatment was 9 (3-17) and 5 (2-9) yr, respectively. GH-treated women had a slightly greater ( approximately 8%, P = 0.03) width of the radial shaft, but otherwise there were no significant differences between groups in bone dimensions or BMD at the distal radius, lumbar spine, or femoral neck. Furthermore, regression analysis in a linear model including independent variables of age, age at diagnosis, body mass index, presence of spontaneous puberty, and GH use confirmed that GH use did not contribute to variation in BMD.
Bakalov
Vladimir K
VK
Developmental Endocrinology Branch, National Institute of Child Health and Human Development, National Institutes of Health, Bethesda, Maryland 20892 , USA. bakalov@mail.nih.gov <bakalov@mail.nih.gov>
Van
Phillip L
PL
Baron
Jeffrey
J
Reynolds
James C
JC
Bondy
Carolyn A
CA
D000293:Adolescent; D000328:Adult; D015519:Bone Density / Q000187:drug effects*; D001847:Bone Diseases / Q000188:drug therapy* / Q000209:etiology; D016022:Case-Control Studies; D002648:Child; D003430:Cross-Sectional Studies; D005260:Female; D005272:Femur Neck; D006130:Growth Disorders / Q000188:drug therapy* / Q000209:etiology; D006621:Hip Joint; D019382:Human Growth Hormone / Q000627:therapeutic use*; D006801:Humans; D008159:Lumbar Vertebrae; D014424:Turner Syndrome / Q000150:complications*
D019382:Human Growth Hormone